Martin Zügel

Dr. Martin Zügel was born on 6 April 1962. After studying medicine in Bochum and Tübingen and molecular biology (MSc) in Amherst, USA, he received his doctorate, Dr. med., in 1989.

Dr. Zügel has 30 years of experience in the healthcare sector, covering the full range of the industry. He draws on 20 years of board room experience in executive and non-executive positions, serving companies with global reach across Europe, Asia and the US.

After working in the hematology and oncology departments of the University Hospital Hamburg-Eppendorf (UKE), he switched to Boehringer Mannheim GmbH (later Hoffmann La Roche AG) in 1991 and joined B. Braun Melsungen AG as a Member of the Board in 2000. In 2005, he became part of the pharmaceutical company Merz as CEO of Merz Pharmaceuticals, and starting in 2008, he assumed the additional role of Spokesperson for Merz GmbH & Co. KGaA. Since his departure from Merz in 2012, Dr. Zügel has acted as Chairman of the Supervisory Board (Glycotope and Amsilk GmbH) and as a consultant for various companies in the pharmaceutical and biotech industry, and also as Senior Health Care Advisor for the private equity firm CVC Capital Partners. From 2015 to 2019, Dr. Zügel also served as Chief Executive Officer of Klosterfrau Zürich AG, a foundation-owned strategic holding that owns five companies in the healthcare and consumer sectors.